M-VAC Monotherapy for Advanced Transitional Cell Carcinoma of the Bladder.
- Author:
Jeong Zoo LEE
1
;
Jong Byung YOON
Author Information
1. Department of Urology, College of Medicine, Pusan National University, Pusan, Korea.
- Publication Type:Original Article
- Keywords:
M-VAC Chemotherapy;
Advanced bladder cancer
- MeSH:
Carcinoma, Transitional Cell*;
Cisplatin;
Doxorubicin;
Drug Therapy;
Dysuria;
Hematuria;
Humans;
Liver;
Methotrexate;
Neoplasm Metastasis;
Retrospective Studies;
Urinary Bladder*;
Vinblastine
- From:Korean Journal of Urology
1990;31(6):807-813
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We retrospectively reviewed eleven patients with advanced bladder carcinoma (T3b-4) who were treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) chemotherapy alone. 1. The mean age and the cycle were 64 years ( 50-75) and 4.7 cycles ( 1-II) respectively. 2. In primary lesions, four (36.4 per cent) showed partial response, six (54.5 per cent) minor response and one (9.1 per cent) clinically stable, and therefore response rate was 36.4 per cent. There was no case of complete remission. In extravesical lesions, progression was seen in a case of liver metastasis and no remarkable changes was seen in bone metastatic case. 3. Maximal effect of clinical response was observed after completion of 3-4 cycles in cases of partial remission. 4. There were marked improvement of clinical symptoms such as loss of hematuria and dysuria during 1 or 2 cycles of chemotherapy. Even though there was no case of complete remission in our cases, 3-4 cycles of M-VAC monotherapy may be considered as a kind of treatment of the advanced transitional cell carcinoma or bladder in selected cases.
